Adverum Biotechnologies, Inc.
ADVM
$4.20
$0.030.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 1.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 1.00M |
| Cost of Revenue | 1.08M | 37.13M | 28.75M | 24.10M | 1.09M |
| Gross Profit | -1.08M | -37.13M | -28.75M | -24.10M | -86.00K |
| SG&A Expenses | 9.11M | 12.73M | 19.47M | 38.12M | 15.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.02M | 49.86M | 48.22M | 62.22M | 35.44M |
| Operating Income | -48.02M | -49.86M | -48.22M | -62.22M | -34.44M |
| Income Before Tax | -47.65M | -49.19M | -47.02M | -60.53M | -32.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.65M | -49.19M | -47.02M | -60.53M | -32.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.65M | -49.19M | -47.02M | -60.53M | -32.35M |
| EBIT | -48.02M | -49.86M | -48.22M | -62.22M | -34.44M |
| EBITDA | -47.56M | -49.32M | -47.54M | -61.41M | -33.55M |
| EPS Basic | -2.03 | -2.34 | -2.25 | -2.90 | -1.55 |
| Normalized Basic EPS | -1.27 | -1.46 | -1.40 | -1.81 | -0.97 |
| EPS Diluted | -2.03 | -2.34 | -2.25 | -2.90 | -1.55 |
| Normalized Diluted EPS | -1.27 | -1.46 | -1.40 | -1.81 | -0.97 |
| Average Basic Shares Outstanding | 23.49M | 21.01M | 20.94M | 20.90M | 20.88M |
| Average Diluted Shares Outstanding | 23.49M | 21.01M | 20.94M | 20.90M | 20.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |